This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1988 Mar;6(3):403-6.

doi: 10.1200/JCO.1988.6.3.403.

Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans

S A Rosenberg¹

Affiliations

PMID: 3258361
DOI: 10.1200/JCO.1988.6.3.403

Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans

S A Rosenberg. J Clin Oncol. 1988 Mar.

. 1988 Mar;6(3):403-6.

doi: 10.1200/JCO.1988.6.3.403.

Author

S A Rosenberg¹

Affiliation

¹ National Cancer Institute, Bethesda, MD.

PMID: 3258361
DOI: 10.1200/JCO.1988.6.3.403

No abstract available

PubMed Disclaimer

Similar articles

[Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
Robak T. Robak T. Pol Tyg Lek. 1988 Nov 21;43(47):1491-5. Pol Tyg Lek. 1988. PMID: 3266975 Polish. No abstract available.
Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA. Rosenberg SA. Important Adv Oncol. 1986:55-91. Important Adv Oncol. 1986. PMID: 3330541 Review. No abstract available.
Immunotherapy of cancer using interleukin 2: current status and future prospects.
Rosenberg SA. Rosenberg SA. Immunol Today. 1988 Feb;9(2):58-62. doi: 10.1016/0167-5699(88)91261-3. Immunol Today. 1988. PMID: 3076761 Review. No abstract available.
Human interleukin 2: molecular biology, physiology and clinical possibilities.
Mertelsmann R, Welte K. Mertelsmann R, et al. Immunobiology. 1986 Sep;172(3-5):400-19. doi: 10.1016/S0171-2985(86)80121-8. Immunobiology. 1986. PMID: 3100434 Review. No abstract available.
[Biological immunomodulators in the treatment of cancer].
Bello C, Richard C, Hermosa V, Iriondo A, Muruzábal MJ, Pérez Encinas M, Zubizarreta A. Bello C, et al. Sangre (Barc). 1988 Apr;33(2):132-43. Sangre (Barc). 1988. PMID: 2456623 Review. Spanish. No abstract available.

See all similar articles

Cited by

Gene therapy for urologic cancer.
Ferrer FA, Rodriguez R. Ferrer FA, et al. Curr Urol Rep. 2002 Feb;3(1):75-81. doi: 10.1007/s11934-002-0014-7. Curr Urol Rep. 2002. PMID: 12084223 Review.
Lymphokine activated killer cells.
Lindemann A, Herrmann F, Oster W, Mertelsmann R. Lindemann A, et al. Blut. 1989 Oct;59(4):375-84. doi: 10.1007/BF00321208. Blut. 1989. PMID: 2676022 Review.
Relevance of the T cell receptor for immunotherapy of cancer.
Weidmann E, Trucco M, Whiteside TL. Weidmann E, et al. Cancer Immunol Immunother. 1994 Jul;39(1):1-14. doi: 10.1007/BF01517174. Cancer Immunol Immunother. 1994. PMID: 8044821 Free PMC article. Review. No abstract available.
Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.
Okuno K, Ohnishi H, Nakajima I, Akabane Y, Kurooka K, Koh K, Shindo K, Yasutomi M. Okuno K, et al. Surg Today. 1994;24(1):80-4. doi: 10.1007/BF01676892. Surg Today. 1994. PMID: 8054783
Is human cell therapy research caught in a mousetrap?
John Barrett A, Joseph Melenhorst J. John Barrett A, et al. Mol Ther. 2011 Feb;19(2):224-7. doi: 10.1038/mt.2010.304. Mol Ther. 2011. PMID: 21289634 Free PMC article. No abstract available.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.